Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab Long-Term Safety in Crohn's Disease
NCT00280956Phase 4Completed
- Sponsor
- Biogen
- Start
- Jul 2002
- Primary completion
- Sep 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of natalizumab in Crohn's disease, sponsored by Biogen. Started Jul 2002; status: completed.
02
Drugs
natalizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00280956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00280956.